medius KLINIKEN gGmbH — Clinical Trial Site

18 Registered trials

5 Currently recruiting

Organisation

medius KLINIKEN gGmbH

Location

Kirchheim Unter Teck, Germany

Identifier

ORG-100042911

Address

Hedelfinger Strasse 166, Ruit, 73760, Germany

Departments

#6005: Klinik für Innere Medizin, Rheumatologie, Pneuomologie, Nephrologie und Diabetologie
Brustzentrum
Frauenheilkunde und Geburtshilfe
Innere Medizin, Gastroenterologie, Tumor- und Palliativmedizin
Internal Medicine
Klinik für Allgemeine Innere Medizin, Gastroenterologie und Tumormedizin
Klinik für Innere Medizin, Gastroenterologie und Tumormedizin
Klinik für Innere Medizin, Rheumatologie und Immunologie Rheumatologische Studienzentrale
Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie
Klinik für Urologie
medius Klinik Nuertingen
NA
Rheumatologie und Immunologie
site 004 - Klinik für Innere Medizin, Diabetologie, Gastroenterologie, Tumor- und Palliativmedizin
Strahlentherapie

Clinical trials at this site (18)

Search interface

ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Not authorised

2022-500536-11-00 Moderately to severely active ulcerative colitis 5
ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised

2022-500537-84-00 Moderately to severely active ulcerative colitis 5
A Randomized Double-Blind, Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART) Pending

2024-515287-31-00 Giant Cell Arteritis 5
Trial of efficacy and safety of NS-229 versus placebo in patients with Eosinophilic Granulomatosis With Polyangiitis Recruiting

2023-504245-32-00 Eosinophilic granulomatosis with polyangiitis (EGPA) 4 2024-06-06
A study to test whether nerandomilast helps people with lung fibrosis related to rheumatic diseases Recruiting

2024-512849-17-00 Systemic Autoimmune Rheumatic Diseases associated Inter 5 2025-11-14
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
Prospective, placebo-controlled clinical trial with Aconite Pain Oil in oncological patients under-going chemotherapy to prevent chemotherap… Recruiting

2022-502889-24-00 chemotherapy-induced polyneuropathy (CIPN) 5 2024-02-13
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for lo… Recruiting

2024-518077-34-00 locally advanced rectal cancer 5 2020-09-30
A randomized, controlled study to evaluate LNP023 (iptacopan) in patients with active ANCA-associated vasculitis. Ended

2023-510525-15-00 active antineutrophilic cytoplasmic antibody (ANCA) ass 4 2024-11-18
Dose-finding study of SAR443122 in adult participants with ulcerative colitis Ended

2022-500290-14-01 Colitis ulcerative 4 2023-05-11
Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer wit… Ended

2024-511209-49-00 Patients with hormone receptor positive HER2 negative l 6 2022-04-26
Phase 3 Study of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis Ended

2023-506359-68-00 Active Proliferative Lupus Nephritis 5 2022-04-08
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined… Ended

2024-511577-29-01 intermediate and high-risk rectal cancer 5 2020-03-13
Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab. Ended

2023-510248-19-00 Eosinophilic Granulomatosis with Polyangiitis (EGPA) 5 2020-01-21
A phase I/II trial of D,L-MEthadone and mFOLFOX6 in treatment of advanced colorectal cancer (MEFOX) Ended

2024-519509-37-00 Patients with advanced, histologically confirmed, metas 9 2025-02-25
CIRCULATE Ended

2023-506715-18-00 colon cancer stage II, rectal cancer stage II 5 2019-12-04
Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of… Ended

2024-512934-14-00 advanced or metastatic adenocarcinoma of the stomach or 5 2016-11-07